Los Angeles Times

Hepatitis C drug can be a bargain

-

Re “Here’s why drugmakers are held in low esteem,” Column, Aug. 28

Regarding the exorbitant price of Harvoni, the new hepatitis C drug, David Lazarus writes that it costs $95,000 for a course of treatment. This is misleading.

Most insurance companies have negotiated with Gilead Sciences, the drug’s maker, for, on average, a price 46% lower than list, according to the company. It costs even less for people who need only eight weeks of treatment. Additional­ly, patients without insurance or with unaffordab­le copays can obtain assistance from the company.

In years past, hepatitis C required a drug combinatio­n that worked about 50% of the time. The drugs required not 12 or eight weeks like Harvoni but anywhere from 24 to 48 weeks, at an average price of $25,000, which had to be repeated in cases of nonrespons­e. The drugs often caused expensive-to-treat complicati­ons of their own and prevented people from working.

If you do the math, Harvoni’s actual price is right in line. And it works in more than 90% of cases and with few side effects.

Yes, this is wrong, but comparing it to the price of diabetes care over the course of a lifetime, you have a veritable bargain.

Barbara Kaplan

Los Angeles

Janusz Ordovar, a former deputy assistant attorney general under President George H.W. Bush who was quoted by Lazarus, thinks Americans actually believe that high drug prices are necessary to encourage research into new drugs.

So, Ordovar would have us believe that only Americans should support pharmaceut­ical research, while the rest of the developed world pays much less?

How much longer should we have to listen to this canard? It’s bad enough that U.S. consumers pay more for healthcare than the rest of the world for a system that delivers mediocre results.

There’s a simple explanatio­n for high drug costs in America: The pharmaceut­ical industry is propping up politician­s’ increasing­ly expensive election campaigns with money that’s intended to maintain the status quo of ever-increasing drug prices.

Greg Ryan

Woodland Hills

Newspapers in English

Newspapers from United States